AU2002348022B2 - Anhydrous crystal form of valaciclovir hydrochloride - Google Patents
Anhydrous crystal form of valaciclovir hydrochloride Download PDFInfo
- Publication number
- AU2002348022B2 AU2002348022B2 AU2002348022A AU2002348022A AU2002348022B2 AU 2002348022 B2 AU2002348022 B2 AU 2002348022B2 AU 2002348022 A AU2002348022 A AU 2002348022A AU 2002348022 A AU2002348022 A AU 2002348022A AU 2002348022 B2 AU2002348022 B2 AU 2002348022B2
- Authority
- AU
- Australia
- Prior art keywords
- valaciclovir hydrochloride
- anhydrous crystalline
- hydrochloride
- anhydrous
- crystalline valaciclovir
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Communicable Diseases (AREA)
- Pharmacology & Pharmacy (AREA)
- Oncology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US33331301P | 2001-11-05 | 2001-11-05 | |
| US60/333,313 | 2001-11-05 | ||
| PCT/US2002/033926 WO2003040145A1 (en) | 2001-11-05 | 2002-10-23 | Anhydrous crystal form of valaciclovir hydrochloride |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2002348022A1 AU2002348022A1 (en) | 2003-07-24 |
| AU2002348022B2 true AU2002348022B2 (en) | 2006-06-15 |
Family
ID=23302261
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2002348022A Ceased AU2002348022B2 (en) | 2001-11-05 | 2002-10-23 | Anhydrous crystal form of valaciclovir hydrochloride |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20040197396A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP1453834A1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2005511612A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2002348022B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2465420A1 (cg-RX-API-DMAC7.html) |
| FR (1) | FR2831885A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB2383038B (cg-RX-API-DMAC7.html) |
| GR (1) | GR1004358B (cg-RX-API-DMAC7.html) |
| IT (1) | ITRM20020555A1 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2003040145A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1551880A (zh) * | 2001-09-07 | 2004-12-01 | ������ҩ��ҵ����˾ | 阿昔洛韦缬氨酸酯盐酸盐的晶型 |
| WO2003040145A1 (en) * | 2001-11-05 | 2003-05-15 | Glaxo Group Limited | Anhydrous crystal form of valaciclovir hydrochloride |
| IL161969A0 (en) * | 2001-11-14 | 2005-11-20 | Teva Pharma | Synthesis and purification of valacyclovir |
| US20050043329A1 (en) * | 2002-09-06 | 2005-02-24 | Shlomit Wizel | Crystalline forms of valacyclovir hydrochloride |
| US20060229322A1 (en) * | 2002-12-09 | 2006-10-12 | Pau Cid | Anhydrous crystalline form of valacyclovir hydrochloride |
| WO2004106338A1 (en) * | 2003-05-30 | 2004-12-09 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. | Novel crystalline forms of valacyclovir hydrochloride |
| TW200510414A (en) * | 2003-06-02 | 2005-03-16 | Teva Pharma | Novel crystalline forms of valacyclovir hydrochloride |
| CN1331471C (zh) * | 2003-09-22 | 2007-08-15 | 陈云芳 | 盐酸万乃洛韦软胶囊组合物 |
| EP1746098A1 (en) * | 2005-07-21 | 2007-01-24 | SOLMAG S.p.A. | Valacyclovir polymorphs and a process for the preparation thereof |
| US20080167325A1 (en) * | 2006-12-27 | 2008-07-10 | Bs Praveen Kumar | Valacyclovir compositions |
| JPWO2009031576A1 (ja) * | 2007-09-03 | 2010-12-16 | 味の素株式会社 | バラシクロビル塩酸塩結晶の製造方法 |
| WO2011158252A1 (en) | 2010-06-15 | 2011-12-22 | Matrix Laboratories Ltd | Process for the preparation of valacyclovir hydrochloride polymorphic form ii |
| CN105753868B (zh) * | 2016-04-12 | 2017-08-01 | 浙江理工大学 | 一种盐酸伐昔洛韦的半水合物及其制备方法 |
| CN112176011B (zh) * | 2020-10-26 | 2022-10-18 | 辰欣药业股份有限公司 | 一种酶催化制备盐酸伐昔洛韦的方法 |
| CN116754538B (zh) * | 2023-06-15 | 2024-05-07 | 深圳市新阳唯康科技有限公司 | 一种阿昔洛韦软膏的晶型定量方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957924A (en) * | 1987-08-15 | 1990-09-18 | Burroughs Wellcome Co. | Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof |
| US6107302A (en) * | 1995-01-20 | 2000-08-22 | Glaxo Wellcome Inc. | Guanine derivative |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4199574A (en) * | 1974-09-02 | 1980-04-22 | Burroughs Wellcome Co. | Methods and compositions for treating viral infections and guanine acyclic nucleosides |
| GB9501127D0 (en) * | 1995-01-20 | 1995-03-08 | Wellcome Found | Tablet |
| CN1551880A (zh) * | 2001-09-07 | 2004-12-01 | ������ҩ��ҵ����˾ | 阿昔洛韦缬氨酸酯盐酸盐的晶型 |
| WO2003040145A1 (en) * | 2001-11-05 | 2003-05-15 | Glaxo Group Limited | Anhydrous crystal form of valaciclovir hydrochloride |
| IL161969A0 (en) * | 2001-11-14 | 2005-11-20 | Teva Pharma | Synthesis and purification of valacyclovir |
| US20050043329A1 (en) * | 2002-09-06 | 2005-02-24 | Shlomit Wizel | Crystalline forms of valacyclovir hydrochloride |
| EP1551838B1 (en) * | 2002-10-16 | 2006-08-09 | Teva Pharmaceutical Industries Ltd. | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20050059684A1 (en) * | 2002-10-16 | 2005-03-17 | Ben-Zion Dolitzky | Method for reducing residual alcohols in crystalline valacyclovir hydrochloride |
| US20060229322A1 (en) * | 2002-12-09 | 2006-10-12 | Pau Cid | Anhydrous crystalline form of valacyclovir hydrochloride |
| WO2004106338A1 (en) * | 2003-05-30 | 2004-12-09 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ticaret A.S. | Novel crystalline forms of valacyclovir hydrochloride |
| TW200510414A (en) * | 2003-06-02 | 2005-03-16 | Teva Pharma | Novel crystalline forms of valacyclovir hydrochloride |
| JP2007522130A (ja) * | 2004-01-21 | 2007-08-09 | テバ ファーマシューティカル インダストリーズ リミティド | 塩酸バラシクロビルの調製方法 |
| EP1746098A1 (en) * | 2005-07-21 | 2007-01-24 | SOLMAG S.p.A. | Valacyclovir polymorphs and a process for the preparation thereof |
| US20070112193A1 (en) * | 2005-11-14 | 2007-05-17 | Khunt Mayur D | Valacyclovir process |
-
2002
- 2002-10-23 WO PCT/US2002/033926 patent/WO2003040145A1/en not_active Ceased
- 2002-10-23 JP JP2003542191A patent/JP2005511612A/ja active Pending
- 2002-10-23 AU AU2002348022A patent/AU2002348022B2/en not_active Ceased
- 2002-10-23 US US10/494,115 patent/US20040197396A1/en not_active Abandoned
- 2002-10-23 EP EP02784234A patent/EP1453834A1/en not_active Withdrawn
- 2002-10-23 CA CA002465420A patent/CA2465420A1/en not_active Abandoned
- 2002-11-04 FR FR0213752A patent/FR2831885A1/fr not_active Withdrawn
- 2002-11-05 GR GR20020100478A patent/GR1004358B/el unknown
- 2002-11-05 GB GB0225771A patent/GB2383038B/en not_active Expired - Fee Related
- 2002-11-05 IT IT000555A patent/ITRM20020555A1/it unknown
-
2006
- 2006-10-24 US US11/552,218 patent/US20070093511A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4957924A (en) * | 1987-08-15 | 1990-09-18 | Burroughs Wellcome Co. | Therapeutic valine esters of acyclovir and pharmaceutically acceptable salts thereof |
| US6107302A (en) * | 1995-01-20 | 2000-08-22 | Glaxo Wellcome Inc. | Guanine derivative |
Also Published As
| Publication number | Publication date |
|---|---|
| GR1004358B (el) | 2003-10-07 |
| GB0225771D0 (en) | 2002-12-11 |
| US20040197396A1 (en) | 2004-10-07 |
| ITRM20020555A0 (it) | 2002-11-05 |
| US20070093511A1 (en) | 2007-04-26 |
| JP2005511612A (ja) | 2005-04-28 |
| GR20020100478A (el) | 2003-07-16 |
| GB2383038B (en) | 2005-01-19 |
| CA2465420A1 (en) | 2003-05-15 |
| FR2831885A1 (fr) | 2003-05-09 |
| GB2383038A (en) | 2003-06-18 |
| WO2003040145A1 (en) | 2003-05-15 |
| EP1453834A1 (en) | 2004-09-08 |
| ITRM20020555A1 (it) | 2003-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20040197396A1 (en) | Anhydrous crystal form of valaciclovir hydrochloride | |
| JP7355834B2 (ja) | 固体形態のfgfr阻害剤化合物およびその製造方法 | |
| AU2002348022A1 (en) | Anhydrous crystal form of valaciclovir hydrochloride | |
| WO2019232138A1 (en) | Crystalline form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3) pyridazine-3-carboxamide | |
| MXPA06002761A (es) | Forma cristalina de sal de calcio de bis [(e)-7-[4 -(4-fluorofenil)- 6-isopropil- 2-[metil(metilsulfonil) amino] pirimidin -5-il](3r, 5s)-3, 5-dihidroxihept -6-acido enoico]. | |
| JP2021063111A (ja) | 二メシル酸パルボシクリブの固体形態 | |
| WO2022165141A1 (en) | Crystal form of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1h-1,2,4-triazol-3-yl)phenyl)amino)-n-(methyl-d3)pyridazine-3-carboxamide | |
| EP2216329A1 (en) | Processes for the preparation of tadalafi | |
| GB1580782A (en) | Pharmaceutical compositions alkenyl xanthines contained therein and processes for their preparation | |
| EP0976750A1 (en) | Novel z-valacyclovir crystals | |
| DK2370440T3 (en) | 8-Chloro-3-pentyl-3,7-dihydro-1H-purine-2,6-dion2-amino-2- (hydroxymethyl) -1,3-propandiolanhydrat for the treatment of diseases | |
| CN102282148A (zh) | 11-(2-吡咯烷-1-基-乙氧基)-14,19-二氧杂-5,7,26-三氮杂-四环[19.3.1.1(2,6).1(8,12)]二十七碳-1(25),2(26),3,5,8,10,12(27),16,21,23-十烯柠檬酸盐 | |
| US20090076270A1 (en) | Drying process for preparing crystalline solid famciclovir | |
| EP2899193A1 (en) | Crystalline form of abacavir that is essentially free of solvent | |
| JP7434273B2 (ja) | アゼチジン誘導体のボレート | |
| JP2025128032A (ja) | ダプロデュスタットの共結晶 | |
| CN109516976B (zh) | 取代嘧啶类pi3k抑制剂甲磺酸盐的晶型及其制备方法 | |
| CA1234810A (en) | Non-hygroscopic adinazolam methanesulfonate salt and process therefor | |
| WO2017108927A1 (en) | Process for preparation of ingenol 3-(3.5-diethylisoxazole-4-carboxylate) | |
| WO2004089952A1 (en) | Novel crystalline forms of abacavir sulfate | |
| WO2017032705A1 (en) | Crystalline form of omarigliptin | |
| AU2024379244A1 (en) | 2-(4-(2-(7, 8-dimethyl-[1,2,4]triazolo[1,5-a] pyridin-6-yl)-3-isopropyl-1h-indol-5-yl)piperidin-1-yl)acetamide salt and crystalline forms thereof | |
| WO2003011863A1 (en) | Novel crystal forms of 9-substituted hypoxanthine derivatives | |
| AU2001238565A1 (en) | Novel crystal forms of 9-substituted hypoxanthine derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |